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osity, comorbid burden using a method of risk adjustment based
on pharmacy claims, and Part D uptake after adjusting for
patients’ demographic characteristics, characteristics of pre-Part
D prescription use (average 2005 annual copayments, number of
prescriptions, drug utilization in pill-days, number of treatment
classes as reported in the store data), pre-Part D Medicaid eligi-
bility, and zip code linked USA Census data. RESULTS: After
multivariate adjustment, each 10% increase in 2005 insurance
generosity was associated with a 16% lower likelihood of Part D
utilization and each standard deviation increase in comorbid
score was associated with an 8% greater likelihood of Part D
utilization. Beneﬁciaries with the lowest yet positive insurance
generosity with the greatest comorbid burden were up to 2.5
times more likely to utilize Part D than people who had generous
insurance and were the healthiest before the introduction of the
program (60.65% vs. 37.56%, p < 0.001). Results were robust
to numerous sensitivity analyses. CONCLUSION: We ﬁnd sig-
niﬁcantly higher rates of beneﬁt adoption among subjects with
low pre-Part D prescription coverage and high pre-Part D comor-
bid burden. Our ﬁndings highlight the fact that implementation
and uptake of changes in health policy are seldom uniform.
These results also may be useful in welfare analyses of Part D,
and they demonstrate the importance of considering non-random
selection into Part D when considering the impact of Part D on
processes or outcomes of care.
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OBJECTIVE: To evaluate the effect of Medicare new drug beneﬁt
(Part D) on utilization of psychotropic medications and the con-
sequent ﬁnancial burden for elderly. METHODS: The effect of
Medicare Part D was measured using 24 months pharmacy
claims collected from one of the largest retail pharmacy chains in
the United States. Among the approximately 70 million individu-
als who ﬁlled prescriptions at the pharmacy chain in 2006, 11%
were 65 years or older. Segmented regression of interrupted
time series analysis was employed to evaluate population level
changes in the utilization of three most commonly used psycho-
tropic therapeutic categories among elderly, namely antidepres-
sants, antipsychotics and benzodiazepines. RESULTS: Since Part
D came into effect, the proportion of out-of-pocket payment in
total pharmacy reimbursement decreased 18% for antidepres-
sants (net saving: $4.5 per prescription) and 21% for antipsy-
chotics (net saving: $5.7 per prescription). In contrast, the out-
of-pocket share the elderly paid for benzodiazepines increased
19% (net increase: $2.8 per prescription). Part D implementation
was associated with signiﬁcant month-to-month increase in use
of antidepressants [1679 prescriptions per month (95%CI:719,
2639)] and antipsychotics [567 prescriptions per month (95%
CI:413, 720)]. By December 2006, the antidepressant and antip-
sychotic prescriptions ﬁlled by seniors grew 7% (from 273,166
to 293,590 prescriptions per month, P < 0.001) and 18% (from
41,079 to 48,276 prescriptions per month, P < 0.001) respec-
tively as compared to the expected level estimated based on prior
Part D trend. In contrast, Part D led to an immediate and sus-
tained drop of 5% (from 238,961 to 226,622 prescriptions per
month, P < 0.001) in benzodiazepine prescriptions ﬁlled by
elderly. CONCLUSION: Our ﬁndings revealed that Medicare
Part D improved the access to psychotropic medications covered
under plan through reducing out-of-pocket expenses. However,
the ﬁnancial burden related to psychotropic medications
excluded from the Part D formulary, such as benzodiazepines,
has signiﬁcantly increased.
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The aim of this study was to assess the Rasch measurement
properties of the EQ-5D in respondents with most prevalent
chronic conditions. Medical Expenditures Panel Survey (MEPS)
respondents’ age  18 with complete EQ-5Ds from 2003 were
extracted (n = 19,439). Eleven subgroups were identiﬁed using
the primary ICD-9-CM code for the top 10 chronic conditions
(hypertension, diabetes, depression, back disorder, arthropathy,
cholesterol, asthma, sinusitis, anxiety and joint disorder) as well
as healthy persons (n = 8021). Respondents with perfect scores
demonstrating ceiling (n = 3911) and ﬂoor effects (n = 3) were
removed to ensure uncertainty in the responses. Coding reﬂected
that higher scores represent healthier respondents. The Rasch
rating scale model was used to estimate one set of thresholds for
all items. Unidimensionality was assessed using a z-score ﬁt sta-
tistic, point-biserial correlations and Rasch residual factor analy-
sis. Differential item functioning (DIF) was investigated in a
pooled analysis of the 11 subgroups. Qualitative advances of the
thresholds and positive point-biserial correlations were found
on the EQ-5D items in all subgroups. Residual factor analysis
revealed that a single factor explained between 74.9% and
94.4% of the variance. Further, respondents with different
diseases demonstrated different orders of item difﬁculty. How-
ever, the item “anxiety/depression” consistently showed misﬁt
(z-score > 2.0) in all subgroups. Overall, differential item func-
tioning was found across the 11 subgroups, suggesting that
respondents with different health conditions endorsed items with
different frequency. For the most part, items in the EQ-5D con-
tribute to a single underlying construct and may be used to
evaluate different disease conditions. However, consistent item
misﬁt of the “anxiety/depression” item in all subgroups suggests
that a possible modiﬁcation on this item may be needed.
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The value of qualitative research in the development of Patient-
Reported Outcome (PRO) measures has been recognized for
many years. Very little information is available, however, in the
PRO ﬁeld on the conduct and analysis of qualitative research
compared to the plethora of literature that is readily available on
psychometrics. More recently, the focus has been placed on the
concepts being measured and their meaning, and not in terms
of correlation coefﬁcients or factorial structure, but in their
authenticity for patients. This paper that is authored by an inter-
national, interdisciplinary group of psychologists, psychometri-
cians, regulatory experts, a physician, and a sociologist presents
a method for developing PROs that are based on a foundation of
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rigorous qualitative research. This approach combines grounded
theory methods and is underpinned by an overarching phenom-
enological framework. It is used to develop PRO items and scales
that possess content validity and the ability to yield a measure-
ment model for psychometric testing. This paper will present: 1)
The rationale for the combination of these two schools of quali-
tative research; 2) the current tools that are used that include
semi-structured interviews, a computerized software package,
theoretical sampling, saturation and grounded theory data analy-
sis methods; 3) examples of successful application of qualitative
research to PRO development; and 4) future applications of
qualitative research in upcoming/planned clinical trials.
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OBJECTIVES: In children, utility and health-related quality of
life (HRQOL) measurements may be inﬂuenced by age, cognitive
ability and disease severity. Parents are often proxy respondents.
The objectives were to assess the validity and reliability of a
parent-child dyad utility and HRQOL assessment wherein chil-
dren and parents are interviewed together to assess the child’s
HRQOL. METHODS: The Health Utility Index (HUI), PedsQL
Core and Asthma Modules and the Pediatric Asthma Quality of
Life Questionnaire (PAQLQ) were administered to 93 asthmatic
children aged 8 to 15 years and their parents in a joint dyad
interview. All questions were directed at the child to assess the
child’s utility and HRQOL. Questionnaires were scored nor-
mally. A pre-tested structured guide was available to interview-
ers. To assess construct validity of the dyad approach, Spearman
correlations were calculated between HUI attributes and ques-
tionnaire domains associated with physical function and with
emotional function. Test-retest reliability was assessed with an
intra-class correlation coefﬁcient (ICC) in 28 children who
remained clinically stable between baseline and follow-up assess-
ments at 5 months. RESULTS: Among the parent-child dyads,
the HUI2 Mobility attribute was signiﬁcantly correlated
(p < 0.05) with the PedsQL Core Physical (r = 0.41) and the
PAQLQ Activities (r = 0.32) domains. The HUI2 Emotion
attribute was signiﬁcantly correlated (p < 0.05) with the PedsQL
Core Emotion (r = 0.39), the PedsQL Core Social (r = 0.34), the
PedsQL Asthma Communication (r = 0.21) and the PAQLQ
Emotion (r = 0.25) domains. For clinically stable children, sig-
niﬁcant ICCs between baseline and follow-up were observed for
the HUI2 Total (r = 0.53), PedsQL Core Total (r = 0.70), PedsQL
Asthma Symptoms (r = 0.84), PedsQL Asthma Treatment
(r = 0.51), PAQLQ Activity (r = 0.75) and PAQLQ Emotion
(r = 0.76) domains. CONCLUSIONS: The parent-child dyad
demonstrated moderate construct validity and moderate to
strong test-retest reliability in generic and disease-speciﬁc ques-
tionnaires. This approach may be a valid alternative to relying on
parent proxies for assessing children’s utility and HRQOL.
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The multi-attribute health status (MAHS) approach to develop-
ing indirect utility measures assumes that health preferences are
formed from the simultaneous consideration of multiple health
dimensions. We propose an alternative view that theorizes the
formation of health preferences is mediated by global impres-
sions of quality of life (QL). This study compared the theory of
global health preference formation (GHPF) with the MAHS
approach for explaining time trade-off utilities. A total of 1432
cancer patients completed the EORTC QLQ-C30 and valued
their own current health. A mediation analysis was performed
using latent variable models relating health preferences to QLQ-
C30 domains. Founded on the MAHS approach, Model I
described health preferences using the physical, role, cognitive,
emotional, and social functioning domains (PF, RF, CF, EF, and
SF, respectively) and the fatigue (FA), pain (PA), and nausea/
vomiting (NV) symptom domains. Model II related the QL
domain to the same functioning and symptom domains. Consis-
tent with the GHPF framework, Model III purported that QL
mediated associations of health preferences with functioning
and symptoms. Ignoring QL, health preferences were related
to PF (b = 0.041/p = 0.050), SF (b = 0.057/p = 0.028), and
EF (b = -0.054/p = 0.001). Model II: QL was positively related
to RF (b = 0.222/p = 0.001), EF (b = 0.116/p = 0.001), SF
(b = 0.257/p < 0.001), FA (b = 0.245/p < 0.001), and PA
(b = 0.123/p = 0.001). Model III: QL was positively related to
health preferences (b = 0.117/p < 0.001). Controlling for QL, the
only functioning or symptom domain related to health prefer-
ences was EF (b = -0.067/p < 0.001). Signiﬁcant indirect effects
representing differences between direct effect estimates for
Models I and III were observed for RF (b = 0.026/p = 0.001), EF
(b = 0.014/p = 0.002), SF (b = 0.030/p < 0.001), FA (b = 0.029/
p = 0.003), and PA (b = 0.014/p = 0.002). Model III provided a
signiﬁcantly better ﬁt than Model I (p < 0.001). The MAHS
approach yields misspeciﬁed models of health preferences since
QL mediates associations of the latter with functioning and
symptoms. Our framework has far-reaching implications for
utility assessment and warrants further research.
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OBJECTIVE: More than one-third of patients with diabetes
exhibit poor adherence with recommended drug regimens. While
poor adherence is associated with excess morbidity and mortal-
ity, it is important to realize that better adherence may also affect
short-term health care costs. This research quantiﬁes the effects
of improvements in medication adherence on short-term health
services utilization and their associated costs. METHODS: Data
from Florida: A Healthy State (FAHS), a Medicaid disease man-
agement program developed jointly by Pﬁzer Inc. and the state of
Florida targeting chronically ill Primary Care Case Management
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